Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic ...

The Global Hyperhidrosis Treatment Market Size is projected to grow at a CAGR of 5.89% from 2026 to 2032, according to a new report ...

(Head of Commercial: Mike Petroutsas, "Astellas") today announced final overall survival (OS) results from the Phase 3 EMBARK study evaluating XTANDI ® (enzalutamide), in combination with leuprolide ...

The compelling clinical activity, durable response and acceptable tolerability profile seen with elironrasib underscore the potential of this differentiated RAS (ON) G12C-selective inhibitor, ...

Epidermal growth factor receptor non-small cell lung cancer (EGFR NSCLC) is a lung cancer subtype driven by EGFR gene mutations, leading to rapid tumor growth. It's prevalent particularly in Asian ...

Praxis Precision surges on positive ulixacaltamide data for essential tremor, but tolerability limits impact. Explore PRAX's ...

Detailed price information for Viridian Therapeutics Inc (VRDN-Q) from The Globe and Mail including charting and trades.

DNTH212 is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while ...

Takeda to Receive Rights to Two Next-Generation Late-Stage Investigational Medicines, Worldwide Outside of Greater China, and an Exclusive Option to License Global Rights to an Early-Stage ...

Latest analysis of U.S. real-world evidence demonstrates improved clinical outcomes when cefiderocol is used as earlier ...